RADIOLOGY /// THERAPY RESPONSE EVALUATION

AI-enabled solution to automatically measure and track lesion progression

image description image description

Tempus Pixel provides advanced analysis, tools, and automated reporting from radiology images to help providers accurately track, quantify, and efficiently make RECIST1 assessments and other clinical decisions.

Single-click lesion segmentation

Segment and measure lesions of interest within radiology images for efficient and consistent therapy response assessments2

Automated lesion tracking and reporting

Access longitudinal tracking reports that automatically calculates lesion response3,4

image description

Seamless integration

Easily integrate with existing PACS, EHR, worklist, notification, and dictation systems to optimize radiology workflows

image description
  1. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. Doi: https://doi.org/10.1016/j.ejca.2008.10.026
  2. Tempus Pixel Therapy Response Evaluation single-click lesion segmentation feature is semi-automated and powered by DeepLook’s DL Precise (K202084) but is not available for clinical use in the EU. Arterys is the manufacturer of Tempus Pixel, excluding any third party components described in this list. DeepLook is the manufacturer of DL Precise. DL Precise is not CE marked.
  3. In the U.S., Tempus Pixel Lung is FDA-cleared (K173542) but is not indicated for lung nodule detection. Lung nodule automated detection and quantification is powered by InferRead CT (K192880). Arterys Inc is the manufacturer of Tempus Pixel Lung, excluding any third party components described in this list. Infervision is the manufacturer of InferRead CT.
  4. In the EU, Tempus Pixel Lung is CE marked. RECIST is pending CE mark. Arterys Inc is the manufacturer of Tempus Pixel Lung, excluding any third party components described in this list.

Make more informed decisions with Tempus Pixel